Miller E M, Fowler J F, Kinsella T J
Department of Human Oncology, University of Wisconsin-Madison 53792.
Radiat Res. 1992 Jul;131(1):81-9.
Radiosensitization by iododeoxyuridine (IdU) is a method of enhancing cell killing in the radiotherapy of human cancers, especially for tumors that proliferate faster than the surrounding normal tissues, such as might appear in brain or liver. We have investigated in vitro the relationship between the amount of thymidine replacement by IdU and the resulting radiosensitization in two human colon cancer cell lines, HCT 116 and HT 29, with differing inherent sensitivities to X rays. The results show that an increase in the initial slope of the cell survival curve was the predominant mode of radiosensitization. In this situation, the emphasis on changes in the initial slope suggest the use of a survival curve model that contains the initial slope as a defined variable, which the traditional single-hit, multitarget model does not. We present our analyses mainly in terms of alpha (initial slope) and changes in surviving fraction at 2 Gy and also as a modified form of sensitizer enhancement ratio that describes the dose-modifying factor of IdU at a single radiation dose of 2 Gy (SER 2 Gy). Iododeoxyuridine is an effective radiosensitizer in both cell lines, but IdU appears especially effective in increasing the initial slope of the more radioresistant line, the HT 29 cells.
碘脱氧尿苷(IdU)介导的放射增敏作用是一种在人类癌症放射治疗中增强细胞杀伤的方法,尤其适用于那些比周围正常组织增殖更快的肿瘤,比如可能出现在脑或肝脏中的肿瘤。我们在体外研究了IdU替代胸苷的量与两种对X射线固有敏感性不同的人结肠癌细胞系(HCT 116和HT 29)放射增敏作用之间的关系。结果表明,细胞存活曲线初始斜率的增加是放射增敏的主要方式。在这种情况下,对初始斜率变化的强调表明应使用一种将初始斜率作为定义变量包含在内的存活曲线模型,而传统的单靶、多靶模型则没有该变量。我们主要根据α(初始斜率)以及2 Gy时存活分数的变化进行分析,同时也采用了一种改良形式的增敏剂增强比来描述IdU在2 Gy单一辐射剂量下的剂量修正因子(SER 2 Gy)。碘脱氧尿苷在两种细胞系中都是有效的放射增敏剂,但IdU在增加更具放射抗性的细胞系HT 29细胞的初始斜率方面似乎特别有效。